- Zonisamide Capsules

On April 25, 2022, Glenmark announced a consumer-level recall of several lots of zonisamide capsules due to gaps in the microbiology quality control system or due to lack of stability data.

Product Description	NDC#	Lot# (Expiration Date)
Zonisamide 100 mg capsules	68462-130-01	29200053 (04/30/2023); 29200015 (03/31/2023); 29200016 (03/31/2023); 29200030 (05/31/2023); 29200031 (05/31/2023); 29200032 (05/31/2023); 29200033 (06/30/2023); 29200037 (06/30/2023); 29200038 (06/30/2023); 29200039 (07/31/2023); 29200041 (07/31/2023); 29200042 (07/31/2023); 29200048 (08/31/2023); 29200014 (02/28/2023); 29200050 (08/31/2023); 29200072 (11/30/2023); 29200073 (11/30/2023); 29200074 (11/30/2023); 29200075 (11/30/2023); 29200076 (11/30/2023); 29200049 (08/31/2023)
	68462-130-05	29200014 (02/28/2023); 29200015 (03/31/2023); 29200016 (03/31/2023); 29200054 (04/30/2023)
Zonisamide 25 mg capsules	68462-128-01	29200052 04/30/2023
Zonisamide 50 mg capsules	68462-129-01	29200064 (05/31/2023); 29190043 (05/31/2022); 29190044 (05/31/2022); 29190045 (05/31/2022)

- Zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled zonisamide
- Contact Qualanex by phone at 1-888-504-2012 or by email at recall@qualanex.com for return information and for more information about the recall